Search
The lack of participation in clinical research may be the Achilles’ heel of today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of Memorial Sloan Kettering Cancer Center (MSK), only 35 percent of Americans indicated that they were “likely” to enroll in a clinical trial. Other studies have shown that only 4 percent of cancer patients enroll in clinical trials nationally each year.
The Lehigh Valley Health Network (LVHN) Cancer Institute is now a formal member of the Memorial Sloan Kettering (MSK) Cancer Alliance, a transformative initiative to improve the quality of care and outcomes for people with cancer in community healthcare settings. Representatives of both organizations made the announcement today at Lehigh Valley Hospital–Cedar Crest following an intensive six-month collaborative review process.
Learn about a heartburn-related condition called Barrett’s esophagus and its connection to a higher risk of esophageal cancer.
Prognostic genetic testing is recommended for all patients with chronic lymphocytic leukemia (CLL). However, recent research shows that testing is infrequently performed and outcomes poorer in patients with unfavorable disease risk.
By detecting molecular signatures in the blood, the sensor may help improve cancer screenings.
Memorial Sloan Kettering Cancer Center (MSK) experts shared the results of their latest research at the 65th American Society of Hematology (ASH) Annual Meeting, held in San Diego, December 9 to 12, 2023.
Learn about 14 students who will receive doctoral degrees from the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences at MSK.
Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.
Thetis cells, a class of immune cells first described by MSK researchers in 2022, play an essential and previously unknown role in suppressing inflammatory responses to food, a new study finds.